Finding 1073238 (2023-004)

Significant Deficiency
Requirement
L
Questioned Costs
-
Year
2023
Accepted
2024-09-13
Audit: 319539
Organization: Overdose Lifeline, Inc. (IN)
Auditor: Pile CPAS

AI Summary

  • Core Issue: Revenues earned were not consistently accrued as receivables, violating GAAP revenue recognition standards.
  • Impacted Requirements: Internal controls over financial reporting are inadequate, leading to potential misrepresentation of financial statements.
  • Recommended Follow-Up: Enhance internal controls, provide staff training on revenue recognition, and regularly review accrued revenues to ensure accuracy.

Finding Text

Finding 2023-004 Accounting for Revenues and Accrued Receivables Type of Finding: Significant Deficiency in Internal Control over Financial Reporting Criteria: According to Generally Accepted Accounting Principles (GAAP), revenues must be recorded in the period in which they are earned, even if the claims or payments are received in a subsequent period. Condition: Revenues earned during the fiscal year but claimed in the following fiscal year were inconsistently accrued as receivables. Specifically, revenues related to reimbursement-based grants were not recognized, despite expenses being recorded, and revenues were excluded even though costs of goods sold were included. Cause: The deficiency stemmed from inadequate internal controls and procedures for accruing revenues and receivables, reflecting a failure to adhere to proper revenue recognition practices. Possible or Known Effect: While the adjustments required were not material, they were significant and warrant the attention of those charged with governance. Improper accrual of revenues could mislead financial statement users and impact financial decision-making. Questioned Costs: There are no specific questioned costs identified in this finding. The issue pertains to revenue recognition practices rather than direct disallowed costs. Repeat Finding: This finding is not a repeat finding from the prior year. Recommendation: It is recommended that the organization improve its internal controls and procedures for accruing revenues. This should involve refining procedures for recognizing revenues from reimbursement-based grants and sales of supplies, enhancing staff training on GAAP revenue recognition, and regularly reviewing and reconciling accrued revenues and receivables to ensure they are recorded in the correct period. Significant discrepancies should be reviewed by those charged with governance to ensure timely resolution. Views of Responsible Officials: The Organizations’ Board and Executive Team consisting of the Chief Executive Officer (CEO) and the Chief Operating Officer (COO) and key Overdose Lifeline (ODL) Staff to include the independent bookkeeper and Grant and Finance Manager recognize the need to further refine the internal controls and procedures for accruing revenues. This will be accomplished through the completion of a formal course that covers performing a single audit and consultation with the Independent Public Accounting Firm (Pile CPAs) Additionally staff will regularly meet with the independent bookkeeper to review and reconcile accrued revenues ands receivables.

Categories

No categories assigned yet.

Other Findings in this Audit

  • 496767 2023-001
    Material Weakness
  • 496768 2023-002
    Significant Deficiency Repeat
  • 496769 2023-004
    Significant Deficiency
  • 496770 2023-003
    Significant Deficiency Repeat
  • 496771 2023-005
    Material Weakness
  • 496772 2023-001
    Material Weakness
  • 496773 2023-002
    Significant Deficiency Repeat
  • 496774 2023-004
    Significant Deficiency
  • 496775 2023-003
    Significant Deficiency Repeat
  • 496776 2023-001
    Material Weakness
  • 496777 2023-002
    Significant Deficiency Repeat
  • 496778 2023-004
    Significant Deficiency
  • 496779 2023-001
    Material Weakness
  • 496780 2023-002
    Significant Deficiency Repeat
  • 496781 2023-004
    Significant Deficiency
  • 496782 2023-001
    Material Weakness
  • 496783 2023-002
    Significant Deficiency Repeat
  • 496784 2023-004
    Significant Deficiency
  • 496785 2023-001
    Material Weakness
  • 496786 2023-002
    Significant Deficiency Repeat
  • 496787 2023-004
    Significant Deficiency
  • 496788 2023-001
    Material Weakness
  • 496789 2023-002
    Significant Deficiency Repeat
  • 496790 2023-004
    Significant Deficiency
  • 496791 2023-001
    Material Weakness
  • 496792 2023-002
    Significant Deficiency Repeat
  • 496793 2023-004
    Significant Deficiency
  • 496794 2023-001
    Material Weakness
  • 496795 2023-002
    Significant Deficiency Repeat
  • 496796 2023-004
    Significant Deficiency
  • 1073209 2023-001
    Material Weakness
  • 1073210 2023-002
    Significant Deficiency Repeat
  • 1073211 2023-004
    Significant Deficiency
  • 1073212 2023-003
    Significant Deficiency Repeat
  • 1073213 2023-005
    Material Weakness
  • 1073214 2023-001
    Material Weakness
  • 1073215 2023-002
    Significant Deficiency Repeat
  • 1073216 2023-004
    Significant Deficiency
  • 1073217 2023-003
    Significant Deficiency Repeat
  • 1073218 2023-001
    Material Weakness
  • 1073219 2023-002
    Significant Deficiency Repeat
  • 1073220 2023-004
    Significant Deficiency
  • 1073221 2023-001
    Material Weakness
  • 1073222 2023-002
    Significant Deficiency Repeat
  • 1073223 2023-004
    Significant Deficiency
  • 1073224 2023-001
    Material Weakness
  • 1073225 2023-002
    Significant Deficiency Repeat
  • 1073226 2023-004
    Significant Deficiency
  • 1073227 2023-001
    Material Weakness
  • 1073228 2023-002
    Significant Deficiency Repeat
  • 1073229 2023-004
    Significant Deficiency
  • 1073230 2023-001
    Material Weakness
  • 1073231 2023-002
    Significant Deficiency Repeat
  • 1073232 2023-004
    Significant Deficiency
  • 1073233 2023-001
    Material Weakness
  • 1073234 2023-002
    Significant Deficiency Repeat
  • 1073235 2023-004
    Significant Deficiency
  • 1073236 2023-001
    Material Weakness
  • 1073237 2023-002
    Significant Deficiency Repeat

Programs in Audit

ALN Program Name Expenditures
93.137 Community Programs to Improve Minority Health Grant Program $56,493
93.788 Opioid Str $19,750
21.027 Coronavirus State and Local Fiscal Recovery Funds $18,541